Background:

The aim of this study is to assess whether pupillary modifications following ocular anticholinergic and cholinergic drugs can identify subjects with neurodegenerative diseases from early stages.

Methods:

51 subjects were divided into 3 groups, according to different neurodegenerative diseases, and compared with a control group of 10 patients. Pupil diameter has been measured at different times after topical administration of tropicamide 0.01% in the right eye. Then, topical administration of pilocarpine 0.06% has been performed, followed by pupillary constriction measurement. Pupillary response rates were stratified according to acetylcholinesterase inhibitors intake.

Results:

Observed mydriasis and pupillary constriction was similar in all study groups at all evaluation times. Patients without acetylcholinesterase inhibitors intake presented greater mydriasis.

Conclusions:

Although it was not possible to observe significant differences among groups in terms of pupillary response, the analysis of pupillary features may become an useful tool to detect efficacy of acetylcholinesterase inhibitors.

中文翻译：

---

瞳孔直径作为神经退行性疾病和对乙酰胆碱酯酶抑制剂治疗的反应的可能指标：局部施用托吡卡胺和毛果芸香碱后的深入测量。

 背景：

本研究的目的是评估眼用抗胆碱能药物和胆碱能药物后的瞳孔改变是否可以从早期识别患有神经退行性疾病的受试者。

 方法：

51名受试者根据不同的神经退行性疾病分为3组，并与10名患者的对照组进行比较。在右眼局部施用0.01%托吡卡胺后的不同时间测量瞳孔直径。然后，局部给予0.06%毛果芸香碱，然后进行瞳孔收缩测量。根据乙酰胆碱酯酶抑制剂的摄入量对瞳孔反应率进行分层。

 结果：

所有研究组在所有评估时间观察到的瞳孔散大和瞳孔收缩相似。未摄入乙酰胆碱酯酶抑制剂的患者出现更大的瞳孔散大。

 结论：

尽管不可能观察到各组之间瞳孔反应的显着差异，但瞳孔特征的分析可能成为检测乙酰胆碱酯酶抑制剂功效的有用工具。